Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:FLGT

Fulgent Genetics Q3 2026 Earnings Date & Estimates

Fulgent Genetics logo
$21.74 +0.92 (+4.42%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$21.73 -0.01 (-0.05%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics is scheduled to report Q3 2026 earnings on Friday, November 6, 2026. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Fulgent Genetics in Q3 2026

Fulgent Genetics is expected to post earnings of -$0.65 per share on revenue of $86.30 million. In the same quarter a year earlier Fulgent Genetics reported $0.14 per share on revenue of $84.07 million. Fulgent Genetics last reported on July 30, 2026, posting -$0.58 per share and missing the -$0.46 consensus estimate. Fulgent Genetics has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.65
Expected Revenue
$86.30 million
Prior-Year EPS
$0.14
Prior-Year Revenue
$84.07 million
Expected EPS Growth
-564.3%
Expected Revenue Growth
+2.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.58 (Missed by -$0.12)
Last Quarter Revenue
$85.39 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q3 2026 Call

Fulgent Genetics Q3 2026 Earnings FAQ

Fulgent Genetics (NASDAQ:FLGT) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026.

Fulgent Genetics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Fulgent Genetics to post earnings of -$0.65 per share for Q3 2026.

The consensus revenue estimate for Fulgent Genetics is $86.30 million for Q3 2026.

Fulgent Genetics Earnings Headlines

Fulgent Genetics (NASDAQ:FLGT) versus The Ensign Group (NASDAQ:ENSG) Critical Survey
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086132
HCA Healthcare (NYSE:HCA) & Fulgent Genetics (NASDAQ:FLGT) Financial Contrast
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085850
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
October 11 at 1:00 AM  |  Stansberry Research (Ad)
Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
August 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/fulgent-genetics-flgt-q2-2026-021451513.html
Fulgent Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933475-fulgent-genetics-inc-2026-q2-results-earnings-call-presentation
Piper Sandler Reaffirms Their Hold Rating on Fulgent Genetics (FLGT)
August 2, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/FLGT/pressreleases/3593655/piper-sandler-reaffirms-their-hold-rating-on-fulgent-genetics-flgt/
See More Fulgent Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fulgent Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fulgent Genetics and other key companies, straight to your email.

About Fulgent Genetics

Fulgent Genetics (NASDAQ:FLGT) is a technology-driven clinical diagnostics company that provides genetic testing and laboratory services. The company uses next-generation sequencing and other molecular testing technologies to support the diagnosis, risk assessment and management of inherited diseases, cancer and other medical conditions.

Its offerings include hereditary disease testing, oncology testing, reproductive health testing and specialized genetic panels. Fulgent also provides laboratory-developed tests, pharmacogenetic testing and testing solutions for healthcare providers, hospitals, health systems, employers, pharmaceutical companies and public health organizations. The company previously provided large-scale COVID-19 testing services and has since focused on expanding its broader clinical diagnostics and precision medicine capabilities.

Fulgent Genetics was founded in 2011 and is headquartered in Temple City, California. Its services are primarily offered in the United States, with the company working with healthcare and institutional customers across multiple regions. Ming Hsieh, who founded the company, serves as its chairman and chief executive officer.

View Fulgent Genetics Profile
Earnings Tools